Thiamazole, also known as methimazole, is a medication used to treat hyperthyroidism. This includes Graves' disease, toxic multinodular goiter, and thyrotoxic crisis. It is taken by mouth. Full effects may take a few weeks to occur. Mechanistically, thiamazole inhibits thyroid peroxidase, reducing iodination of thyroglobulin and the coupling of iodotyrosyl residues, which lowers synthesis of thyroxine (T4) and triiodothyronine (T3). It is well absorbed after oral dosing, reaches peak plasma concentrations within 1 to 2 hours, and has an elimination half-life typically in the range of approximately 5 to 13 hours (varies by individual). Thiamazole crosses the placenta and is excreted in breast milk, so pregnancy and lactation require specialist assessment. Typical adult dosing varies with disease severity and treatment strategy (for example block and replace versus titration), and laboratory monitoring of thyroid function, complete blood count and liver enzymes is standard during therapy.
Parent: Thiamazole/ Methimazole
Parent: Thiamazole/ Methimazole
Parent: Thiamazole/ Methimazole
Active pharmaceutical ingredient batches of thiamazole are produced and tested to limit impurities and related compounds. Common related substances encountered analytically include 2-mercaptoimidazole (desulfurized or unmethylated species), methylation positional isomers, small amounts of disulfide dimers and trace oxidative products. Typical quality control criteria used by manufacturers and pharmacopeial monographs set limits such that any single unspecified impurity is generally not more than 0.5 percent of the batch and the total of all unspecified impurities is commonly kept below 2.0 percent (limits may differ by manufacturer and regulatory authority). Residual solvents and heavy metals are controlled per ICH guidance (for example Class 2 and Class 1 solvent limits and elemental impurity limits), and water content is measured by validated methods. For clinical use, finished product specifications also include assay of active content, dissolution or disintegration as appropriate, and stability-indicating testing to ensure impurities remain within specification over shelf life.
Thiamazole reduces production of thyroid hormones by inhibiting thyroid peroxidase, which decreases iodination and coupling reactions required to make T4 and T3. The result is lower circulating thyroid hormone levels and clinical improvement of thyrotoxicosis over several weeks. Therapy is tailored by clinicians based on biochemical tests and clinical response.
Common adverse effects include skin rash, pruritus, nausea and arthralgia. Serious but less frequent reactions include agranulocytosis or severe neutropenia, hepatotoxicity and vasculitis. Because agranulocytosis can present with fever or sore throat, patients are usually advised to seek immediate medical attention if those symptoms occur. Periodic monitoring of complete blood count and liver function tests is recommended according to local guidance.
Yes, Thiamazole is an alternative name for methimazole; they refer to the same chemical entity and are used interchangeably in clinical and regulatory contexts.
Avoid becoming pregnant without medical advice, as antithyroid therapy during early pregnancy requires specialist management and alternative agents may be considered. Do not take additional iodine-containing supplements or medications unless directed by a clinician, because excess iodine can alter treatment response. Avoid abrupt discontinuation of therapy without physician guidance. Report fever or sore throat promptly so clinicians can check blood counts. Follow recommendations on concomitant drugs and laboratory monitoring from your prescriber.
